Engineered immune cells target two cancer markers in new trial

NCT ID NCT05438368

Recruiting now Disease control Sponsor: Shenzhen Geno-Immune Medical Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of cell therapy called GD2/CD70 bi-specific CAR-T cells for people with cancers that have GD2 or CD70 markers on their tumors. The treatment involves taking a patient's own immune cells, modifying them to recognize and attack these markers, and infusing them back into the body. The goal is to see if this approach is safe and can shrink tumors in patients whose cancer has not responded to standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

GD2/CD70 bi-specific CAR-T cells

What this could lead to

If successful, this approach could offer a new treatment option for patients with certain hard-to-treat cancers that express GD2 or CD70 markers.

What could go wrong

This is an early-phase trial with a small number of participants, so the treatment may not work for everyone and could cause significant side effects. Long-term effectiveness and safety are not yet known.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates